Company intelligence
Elicera Therapeutics AB
Prolonging life and increasing life quality of cancer patients through innovative immunotherapies. Learn more.
About Elicera Therapeutics AB
Elicera Therapeutics is a clinical stage cell and gene therapy company focusing on immunooncology. The company develops CAR T-cells against both solid and liquid tumors based on its proprietary technology platform, iTANK, for a parallell activation of an innate immune response against cancer. Elicera also develops next generation oncolytic viruses with three combined mode-of-actions, applicable for treatment of most cancers.
Verified activity
Signals from Elicera Therapeutics AB
3 published signals
Presence & Recognition
Elicera Therapeutics AB is attending Nordic Life Science Days in Stockholm this week, represented by CEO Johan Liwing and outgoing CEO Jamal El-Mosleh.
Reported by Elicera Therapeutics AB
Presence & Recognition
Elicera Therapeutics AB announced that Johan Liwing is the new CEO of the company, appearing in a short video interview with Redeye discussing his background, priorities for Elicera, and recent developments in the CARMA study and patent portfolio.
Reported by Elicera Therapeutics AB
Legal & Regulatory
Elicera Therapeutics AB received its first Notice of Allowance from the Japan Patent Office for ELC-201, a next-generation oncolytic virus candidate for solid tumors.
Reported by Elicera Therapeutics AB